Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
Clinical trial NCT06566807 · RECRUITING
Trial details
- NCT number
- NCT06566807
- Sponsor
- Huai'an First People's Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-25
- Primary completion
- 2026-08-10
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.